Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
People with HIV and HCV co-infection who have fibrosis stages F2 and above should be prioritised for new anti-HCV therapies

People with HIV and hepatitis C virus (HCV) co-infection who have advanced liver fibrosis should be prioritised for therapy with new anti-HCV drugs, investigators argue in AIDS.

Published
1 hour ago
By
Michael Carter
National study finds life-threatening barriers in access to breakthrough drugs

Most states violate federal Medicaid law because they deny coverage for sofosbuvir, a new and highly effective treatment to cure hepatitis C, according to Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection Program. Taylor's team of researchers examined Medicaid policies for hepatitis C virus treatment using sofosbuvir and found that most should change policy to improve access to the treatment.

Published
30 June 2015
From
Eurekalert
FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Specifically, the groups hope to learn about different responses that different patients experienced during clinical trials. Tracy Swan of Treatment Action Group points to relapses in a Harvoni clinical trial that occurred only among African-Americans. The groups also want to perform an independent analysis of poor prognostic factors among people who were not cured in order to identify a patient profile.

Published
29 June 2015
From
Wall Street Journal (blog)
Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy

Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone.

Published
29 June 2015
From
HIVandHepatitis.com
Liver transplants in HIV/HCV co-infection: study underlines importance of hepatitis C treatment

People with HIV and hepatitis C co-infection were significantly more likely to experience organ rejection than people with hepatitis C alone or HIV alone after undergoing a

Published
26 June 2015
By
Keith Alcorn
Hepatitis C Virus Infection and Alcohol: Challenges and Opportunities

This report, prepared by Professor David Goldberg and supported by Bristol Myers-Squibb, looks at the linkages between excessive alcohol consumption and hepatitis C, and explores how excessive alcohol consumption can act as a barrier to people with hepatitis C being considered for, receiving and the benefit of treatment for hepatitis C.

Published
24 June 2015
From
HCV Action
AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

AbbVie, a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.

Published
24 June 2015
From
AbbVie press release
Burman's Specialty Pharmacy study shows hepatitis C cure possible while cutting a third of the drug costs

Burman's Specialty Pharmacy, a Diplomat company, announced a study showing that more than a quarter of hepatitis C patients may be treated with an eight-week therapy, four weeks shorter than the drug manufacturers originally expected. This represents potential for a huge cost savings in a health care ecosystem where hepatitis C treatments have posed a looming problem for payor organizations.

Published
24 June 2015
From
Burman's Specialty Pharmacy press release
China rejects Gilead hepatitis C drug patent: advocacy group

China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.

Published
19 June 2015
From
Reuters
Liver function and survival improve after treatment with Viekirax + Exviera regimen

Hepatitis C patients treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival

Published
18 June 2015
By
Liz Highleyman
← First12345...171Next →

Filter by country